Ro4-1539

Ro4-1539
Legal status
Legal status
  • US: Never FDA approved
Identifiers
IUPAC name
  • 17-(2-(Furan-2-yl)ethyl)-3-hydroxymorphinan
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC22H27NO2
Molar mass337.463 g·mol−1
3D model (JSmol)
SMILES
  • C3CCCC1C35c2cc(O)ccc2CC1N(CC5)CCc4ccco4
  (verify)

Ro4-1539 (furethylnorlevorphanol) is an opioid analgesic drug from the morphinan series that was discovered by the pharmaceutical company Hoffmann–La Roche in the 1950s.[1] It acts as a potent μ-opioid agonist, and was found to be around 30-60 times more potent than the related drug levorphanol in animal experiments.[2][3] Although it has high potency, long duration, and good therapeutic index (1100 in animal studies),[4] Ro4-1539 had no particular clinical advantages over other available opioid drugs, and was never commercially marketed.

Ro4-1539 has never formally undergone clinical trials in humans, but based on its effects in animals it would be expected to produce effects similar to those of other potent opioid agonists, including strong analgesia, sedation, euphoria, constipation, itching, tachyphylaxis and respiratory depression, which could be harmful or fatal.

See also

References

  1. ↑ US 2970147, "3-hydroxy-N-(heterocyclic-ethyl)-morphinans", published 1961-01-31
  2. ↑ Nathan B. Eddy, Hedwig Besendorf and Béla Pellmont. Synthetic analgesics - Aralkyl substitution on nitrogen of morphinan. UNODC Bulletin on Narcotics 1958 p 23-42.
  3. ↑ Hellerbach J, Schnider O, Besendorf H, Pellmont B (1966). "Morphinans". Synthetic Analgesics. Part IIA. Pergamon Press.
  4. ↑ Bulletin on Narcotics October–December 1956 page 37
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.